Sodium butyrate reduces high-fat diet-induced non-alcoholic steatohepatitis through upregulation of hepatic GLP-1R expression

다국어 초록 (Multilingual Abstract)

Glucagon-like peptide-1 (GLP-1) has a broad spectrum of biological activity by regulating metabolic processes via both the direct activation of the class B family of G protein-coupled receptors and indirect nonreceptor-mediated pathways.
GLP-1 receptor (GLP-1R) agonists have significant therapeutic effects on non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) in animal models. However, clinical studies indicated that GLP-1 treatment had little effect on hepatic steatosis in some NAFLD patients, suggesting that GLP-1 resistance may occur in these patients. It is wellknown that the gut metabolite sodium butyrate (NaB) could promote GLP-1 secretion from intestinal L cells. However, it is unclear whether NaB improves hepatic GLP-1 responsiveness in NAFLD. In the current study, we showed that the serum GLP-1 levels of NAFLD patients were similar to those of normal controls, but hepatic GLP-1R expression was significantly downregulated in NAFLD patients. Similarly, in the NAFLD mouse model, mice fed with a high-fat diet showed reduced hepatic GLP-1R expression, which was reversed by NaB treatment and accompanied by markedly alleviated liver steatosis. In addition, NaB treatment also upregulated the hepatic p-AMPK/p-ACC and insulin receptor/ insulin receptor substrate-1 expression levels. Furthermore, NaB-enhanced GLP-1R expression in HepG2 cells by inhibiting histone deacetylase-2 independent of GPR43/GPR109a. These results indicate that NaB is able to prevent the progression of NAFL to NASH via promoting hepatic GLP-1R expression. NaB is a GLP-1 sensitizer and represents a potential therapeutic adjuvant to prevent NAFL progression to NASH.

참고문헌 (Reference)

1 Bedossa, P., "Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease" 60 : 565-575, 2014

2 Smits, M. M., "Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial" 59 : 2588-2593, 2016

3 Zhou, D., "Total fecal microbiota transplantation alleviates high-fat dietinduced steatohepatitis in mice via beneficial regulation of gut microbiota" 7 : 1529-, 2017

4 den Besten, G., "The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism" 54 : 2325-2340, 2013

5 Marchesi, J. R., "The gut microbiota and host health: a new clinical frontier" 65 : 330-339, 2016

6 Wang, F. S., "The global burden of liver disease: the major impact of China" 60 : 2099-2108, 2014

7 Cleophas, M. C., "Suppression of monosodium urate crystal-induced cytokine production by butyrate is mediated by the inhibition of class I histone deacetylases" 75 : 593-600, 2016

8 Zhang, W. H., "Sodium butyrate maintains growth performance by regulating the immune response in broiler chickens" 52 : 292-301, 2011

9 Zhou, D., "Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by improving gut microbiota and gastrointestinal barrier" 23 : 60-75, 2017

10 Tolhurst, G., "Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2" 61 : 364-371, 2012

11 Kaji, I., "Short-chain fatty acid receptor and its contribution to glucagon-like peptide-1 release" 89 : 31-36, 2014

12 Zhou, D., "Prolyl oligopeptidase inhibition attenuates steatosis in the L02human liver cell line" 11 : e0165224-, 2016

13 Rinella, M. E., "Nonalcoholic fatty liver disease" 313 : 2263-, 2015

14 Fan, J. G., "Newtrends on obesity and NAFLD in Asia" 67 : 862-873, 2017

15 Clarke, G., "Minireview: gut microbiota: the neglected endocrine organ" 28 : 1221-1238, 2014

16 Gkolfakis, P., "Gut microbiota and non-alcoholic fatty liver disease" 14 : 572-581, 2015

17 Ben-Shlomo, S., "Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase" 54 : 1214-1223, 2011

18 Gupta, N. A., "Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway" 51 : 1584-1592, 2010

19 Trevaskis, J. L., "Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice" 302 : G762-G772, 2012

20 Svegliati-Baroni, G., "Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis" 31 : 1285-1297, 2011

21 Ao, N., "Glucagon-like peptide-1 preserves nonalcoholic fatty liver disease through inhibition of the endoplasmic reticulum stress-associated pathway" 46 : 343-353, 2016

22 Cd, Graaf, "Glucagon-like peptide-1 and its class B G protein-coupled receptors: a long march to therapeutic successes" 68 : 954-1013, 2016

23 Dhir, G., "Glucagon like peptide-1 receptor agonists for the management of obesity and non-alcoholic fatty liver disease: a novel therapeutic option" 66 : 7-10, 2018

24 Smits, M. M., "GLP-1 based therapies: clinical implications for gastroenterologists" 65 : 702-711, 2016

25 Tremaroli, V., "Functional interactions between the gut microbiota and host metabolism" 489 : 242-249, 2012

26 Guilloteau, P., "From the gut to the peripheral tissues: the multiple effects of butyrate" 23 : 366-384, 2010

27 Ding, X., "Exendin-4, a glucagonlike protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice" 43 : 173-181, 2006

28 Wen, Z. -S., "Effects of sodium butyrate on the intestinal morphology and DNA-binding activity of intestinal nuclear factor-¦ÊB in weanling pigs" 11 : 814-821, 2012

29 Tang, A., "Effects of insulin glargine and liraglutide therapy on liver fat as measured by magnetic resonance in patients with type 2 diabetes: a randomized trial" 38 : 1339-1346, 2015

30 Kleiner, D. E., "Design and validation of a histological scoring system for nonalcoholic fatty liver disease" 41 : 1313-1321, 2005

31 Chambers, E. S., "Control of appetite and energy intake by SCFA: what are the potential underlying mechanisms?" 74 : 328-336, 2015

32 Zhou, D., "Clostridium butyricum B1 alleviates high-fat diet-induced steatohepatitis in mice via enterohepatic immunoregulation" 32 : 1640-1648, 2017

33 Gao, Z., "Butyrate improves insulin sensitivity and increases energy expenditure in mice" 58 : 1509-1517, 2009

34 Steliou, K., "Butyrate histone deacetylase inhibitors" 1 : 192-198, 2012

35 Yadav, H., "Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion" 288 : 25088-25097, 2013

36 Ohira, H., "Are short chain fatty acids in gut microbiota defensive players for inflammation and atherosclerosis?" 24 : 660-672, 2017

37 Park, J. S., "Anti-inflammatory effects of short chain fatty acids in IFN-gamma-stimulated RAW 264.7 murine macrophage cells: involvement of NF-kappaB and ERK signaling pathways" 7 : 70-77, 2007

38 Grasset, E., "A specific gut microbiota dysbiosis of type 2 diabetic mice induces GLP-1 resistance through an enteric NO-dependent and gut-brain axis mechanism" 25 : 1075.e5-1090.e5, 2017

39 Gomez-Lechon, M. J., "A human hepatocellular in vitro model to investigate steatosis" 165 : 106-116, 2007